TrialRMD open2020

Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy.

Matthew Baker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.